|
|
|
 |
FDA Approval Activities for this Drug…
Azulfidine EN-tabs (sulfasalazine) Tablets, 500 mg, Pharmacia & Upjohn NDA 21-243 8/18/00 7/18/01 7/18/01 7/18/01 Azulfidine Indications: for the treatment of pediatric patients with polyarticular course juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. | Azulfidine EN-tabs (sulfasalazine) Tablets, 500 mg, Pharmacia & Upjohn NDA 7-073/S-120 7/30/02 8/6/02 | Azulfidine EN-tabs (sulfasalazine) Tablets, 500 mg, Pharmacia & Upjohn NDA 7-073/S-115 Sulfasalazine Delayed-Release Tablets, 500 mg, Sulfasalazine Delayed-Release Tablets, Vintage ANDA 75-339 1/11/02 | Sulfasalazine Tablets, 500 mg, Vintage ANDA 40-349 SULFASALAZINE Suspension; 250MG/5ML AZULFIDINE PHARMACIA AND UPJOHN | 007073 SULFASALAZINE Tablet, Delayed Release; 500MG AZULFIDINE EN-TABS PHARMACIA AND UPJOHN | 075339 SULFASALAZINE Tablet, Delayed Release; 500MG SULFASALAZINE Vintage | 089590 SULFASALAZINE Tablet; 500MG SULFASALAZINE Mutual | 007073 SULFASALAZINE Tablet; 500MG AZULFIDINE PHARMACIA AND UPJOHN | 040349 SULFASALAZINE Tablet; 500MG SULFASALAZINE Vintage | 085828 SULFASALAZINE Tablet; 500MG SULFASALAZINE Watson | 087197 SULFASALAZINE Tablet; 500MG SULFASALAZINE Watson | Azulfidine (sulfasalazine) Tablets, Pharmacia & Upjohn Co., Labeling Revision | Azulfidine EN-Tabs (sulfasalazine) Tablets, Pharmacia & Upjohn Co., Labeling Revision
  
|